Back

Empagliflozin significantly reduces the capacity of sera to induce endothelial dysfunction in Ischemia Non-Obstructive Coronary Arteries (INOCA): EMbArk phase II pilot trial

29 August 2025 (07:00 - 18:00)
Organised by: Logo
Congress Presentation Part of: Women's cardiovascular disease and pregnancy Cardiovascular Disease in Women ESC Professional Premium Access ESC Congress 2025 European Society of Cardiology

About the speaker

Photo
Doctor Odayme Quesada

The Christ Hospital Health Network, Cincinnati (United States of America)

6 More presentations in this session

Presentation thumbnail
Risks of antihypertensive treatment use in different periods of pregnancy
Professor J. Vaclavik (Ostrava, CZ)
Abstract Slides Video
Presentation thumbnail
Risk factors and prediction model for hypertension in women with hyperandrogenic phenotypes of polycystic ovary syndrome
Doctor A. Stevanovic (Belgrade, RS)
Abstract Slides Video
Presentation thumbnail
Sex differences in trajectory of left ventricular reverse remodelling under contemporary GDMT in recent-onset dilated cardiomyopathy
Doctor Z. Yang (Chengdu - Sichuan, CN)
Abstract Slides Video
Presentation thumbnail
Improving hypertension management in Egyptian women through standardised nurse training on blood pressure measurement
Professor R. Hany Ibrahim (Cairo, EG)
Abstract Slides Video
Presentation thumbnail
Exploring the relationship between testosterone and cardiovascular disease in women
Doctor S. Alexander (Melbourne, AU)
Abstract Slides Video

Access the full session

Session thumbnail
Women's cardiovascular disease and pregnancy

The Event

Event poster

ESC Congress 2025

29 August - 1 September 2025
You may be interested in
thumbnail
Congress Presentation
Empagliflozin significantly reduces circulating markers of endothelial dysfunction in Ischemia with Non-Obstructive Coronary Arteries (INOCA) and coronary microvascular dysfunction: a pilot trial
thumbnail
Congress Presentation
Twelve-months treatment with dapagliflozin improves endothelial glycocalyx and cardiovascular function in patients with type 1 diabetes mellitus
thumbnail
Congress Presentation
Evaluation of coronary microvascular dysfunction and vasospasm in patients with angina and non-obstructive coronary artery disease

ESC 365 is supported by

novartis Explore sponsored resources

ESC 365 is supported by

novartis Explore sponsored resources